Skip to main content
. 2016 Aug 17;7(38):61355–61365. doi: 10.18632/oncotarget.11349

Figure 4. siBARX2 treatment enhances oncogenicity.

Figure 4

(A, B) qRT-PCR analysis and Western blot analysis. Treatment of OSCC cells with siBARX2 oligonucleotide leads to decreased BARX2 mRNA expression (A) and protein expression (B). (C–F) proliferation, migration, invasion, and AIG analysis in HSC3 and OECM1 cells treatment with siBARX2 oligonucleotide. Numbers below pictures represent normalized values. Data are presented as the mean ± SE. *p < 0.05; **p < 0.01; ***p < 0.001; two-way ANOVA or Mann–Whitney test.